CRL logo

CRL

Charles River Laboratories International, Inc.NYSEHealthcare
$173.89-0.58%OpenMarket Cap: $8.56B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

2.70

P/S

2.13

EV/EBITDA

14.24

DCF Value

$115.41

FCF Yield

6.1%

Div Yield

0.0%

Margins & Returns

Gross Margin

32.9%

Operating Margin

10.7%

Net Margin

-3.6%

ROE

-4.4%

ROA

-3.6%

ROIC

7.1%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$994.2M$-276.6M$-5.62
FY 2025$4.02B$-144.3M$-2.91
Q3 2025$1.00B$54.4M$1.10
Q2 2025$1.03B$52.3M$1.06

Analyst Ratings

View All
UBSNeutral
2026-02-25
MizuhoNeutral
2026-02-20
TD CowenBuy
2026-02-20
BarclaysOverweight
2026-02-19
Evercore ISI GroupOutperform
2026-02-19

Trading Activity

Insider Trades

View All
Girshick Birgitofficer: Corporate Executive VP & COO
SellThu Mar 05
FOSTER JAMES Cdirector, officer: Chairman, President and CEO
SellWed Mar 04
LaPlume Joseph Wofficer: EVP, Corp Strategy & Develop
BuyWed Mar 04
LaPlume Joseph Wofficer: EVP, Corp Strategy & Develop
SellTue Feb 03
LaPlume Joseph Wofficer: EVP, Corp Strategy & Develop
SellTue Feb 03

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

1.62

Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Peers